drugset / Trial / NCT03387241
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to severe persistent, reversible asthma.
Timeline
- Start
- 2017-06-02
- Primary completion
- 2019-12-30
- Completion
- 2020-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone | Other / unclassified | 50 ug | Inhaled |
| Comparator | Fluticasone | Other / unclassified | 125 ug | Inhaled |
| Comparator | Fluticasone | Other / unclassified | 250 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 5 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 10 ug | Inhaled |
| Comparator | Salmeterol | Other / unclassified | 25 ug | Inhaled |